Rituximab Market

1. Analysis of Rituximab Market[R1] Size by Research Nester Reveals the Market to Grow with a CAGR of ~16% During 2023-2035 and Attain ~USD 10 Billion by 2035 Research Nester assesses the growth and market size of global rituximab market which is anticipated to be on account of the growing incidences of autoimmune diseases. New York – July 13, 2023- Research Nester’s recent market research analysis on “Rituximab Market: Global Demand Analysis & Opportunity Outlook 2035” delivers a detailed competitor’s analysis and a detailed overview of the global rituximab market in terms of market segmentation by application, distribution channel, and by region.

2. Increasing Investment in Healthcare to Promote Global Market Share of Rituximab The United States has been the main source of money for global health over the past 15 years, and its commitment to the field has grown significantly. The US cancer strategy, known as the Cancer Moonshot, is focusing efforts to accomplish two very significant objectives put forth by the President of the United States: preventing more than four million cancer-related deaths by the year 2047 and enhancing the quality of life for those affected by the disease. The expansion of the rituximab market is being positively influenced by investments and funding in healthcare. Furthermore, it is anticipated that the market for rituximab would expand because to the rising prevalence of non-Hodgkin's lymphoma (NHL). NHL is one of the most prevalent diseases in the USA, according to the American Cancer Society. The number of cases, which were estimated to be at 77,200 in the US in 2020 but are expected to rise sharply as more people develop cancer there. Some of the major growth factors and challenges that are associated with the growth of the global rituximab market are: Growth Drivers: Increasing collaborations for the development of new products · Increasing Demand for Monoclonal Antibodies · Challenges:

3. The high cost of these biosimilars will be the main obstacle to the expansion of the rituximab business over the coming years. The cost of the subcutaneous alternative was higher than the cost of the IV biosimilar rituximab. A higher dose of rituximab may result in long-term issues like a heart attack, ventricular fibrillation (an irregular heart beat), intestinal blockage, or tearing. A significant infection like shingles, other severe renal issues such kidney failure, reactivation of the hepatitis B virus, etc. Access our detailed report at: https://www.researchnester.com/reports/rituximab-market/331 5 By distribution channel, the rituximab market is segmented into hospital pharmacies, retail pharmacies, online pharmacies. The distribution channel segment is segregated among three parts i.e., hospital pharmacies, retail pharmacies and online pharmacies. Among the three, hospital pharmacies are expected to garner the largest revenue during the forecast period. As a result of hospitals using rituximab more frequently for cancer treatment, the hospital sector held a 39.7% share of the overall market in 2022. During the projected period, it is anticipated that rising healthcare spending globally, elevated patient awareness levels, and the availability of world-class hospital facilities in high-income nations would help the industry maintain its leading position. By region, the North America rituximab market is to generate the highest revenue by the end of 2035. North America held a 46.1% share of the global

4. market in 2022 due to its highly developed healthcare system, increased patient awareness, and promising future for cancer research. Increased government funding for cancer research is also anticipated to promote market expansion, as will the presence of large pharmaceutical firms like Pfizer Inc., Amgen Inc., and Merck & Co. Europe is expected to hold the significant share in the market. The market is expected to grow owing to the increasing prevalence of chronic diseases in the region. In spite of having only one-eighth of the world's population, Europe has around one-fourth of all cancer diagnoses, with over 3.7 million new cases diagnosed each year, according to the WHO report. This report also provides the existing competitive scenario of some of the key players of the global rituximab market which includes company profiling of F. Hoffman La Roche Ltd., Pfizer Inc., Sandoz International Inc., Celltrion Healthcare Co. Ltd, Mylan N.V., Teva Pharmaceuticals Industries, Intas Biopharmaceuticals, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA and others. Request Report Sample@ https://www.researchnester.com/sample-request-3315 Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic

5. minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919